FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, specifically to a fused protein containing a variant of rodostomin, and can be used in medicine. An ανβ3 integrin selective polypeptide consisting of an amino acid sequence SEQ ID NO:1 conjugated on the N terminal by a linker amino acid sequence containing a combination of the amino acids glycine and serine with a variant of a human serum albumin (HSA) with SEQ ID NO:4.
EFFECT: invention enables the higher therapeutic effectiveness in the diseases related to ανβ3 integrin.
12 cl, 14 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| αvβ3 SELECTIVE POLYPEPTIDE, METHOD FOR PREPARING IT, POLYNUCLEOTIDE CODING IT, COMPOSITION CONTAINING SAID PEPTIDE, AND METHOD FOR TREATING AND PREVENTING | 2007 |
|
RU2477727C2 |
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| INTEGRIN-TARGETING PROTEIN AND THE METHODS OF ITS USE | 2016 |
|
RU2806524C2 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
| NEW ISOFORMS OF VASCULAR ENDOTHELIAL CELL GROWTH INHIBITOR | 2002 |
|
RU2316591C2 |
| TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αβ-CAUSED ANGIOGENESIS | 1997 |
|
RU2195312C2 |
| CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS | 2003 |
|
RU2346701C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| METHODS AND COMPOSITIONS APPLICABLE FOR MODULATION OF ANTIOGENESIS USING PROTEIN KINASES RAF AND RAS | 2000 |
|
RU2257911C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
